Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors

Analytical Biochemistry

Volumn 394, Issue 1, 2009, Pages 56-61

  LaSala, Daniel ^a   Shibanaka, Yasuhiko ^b   Jeng, Arco Y ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Novartis Institutes for BioMedical Research   (Japan)

Author keywords

11 Hydroxylase; Adrenodoxin; Adrenodoxin reductase; Aldosterone synthase; Enzyme assay; FAD286; Inhibitor

Indexed keywords

BIOCHEMISTRY; BIOSYNTHESIS; CARDIOLOGY; CELL CULTURE; ELECTRON TRANSITIONS; ENZYME ACTIVITY;

ADRENODOXIN; ALDOSTERONE SYNTHASE; ENZYME ASSAYS; FAD286; HYDROXYLASES; INHIBITOR;

ENZYME INHIBITION;

ADRENODOXIN; ALDOSTERONE; ALDOSTERONE SYNTHASE; ALDOSTERONE SYNTHASE INHIBITOR; DEOXYCORTICOSTERONE; ENZYME INHIBITOR; FERREDOXIN NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE REDUCTASE; RECOMBINANT ENZYME; STEROID 11BETA MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN HOMOGENATE; CATALYSIS; CELL LINE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; HEART FAILURE; HORMONE SYNTHESIS; HYPERTENSION; IC 50; IN VITRO STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 69249206536     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2009.07.025     Document Type: Article

References (22)

1. Booth E.B., Johnson J.P., and Stockand J.D. Aldosterone. Adv. Physiol. Educ. 26 (2002) 8-20
2. Connell J.M.C., and Davies E. The new biology of aldosterone. J. Endocrinol. 186 (2005) 1-20
3. Funder J.W. Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade. Future Cardiol. 2 (2006) 535-541
4. George J., and Struthers A.D. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opin. Pharmacother. 8 (2007) 3053-3059
5. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341 (1999) 709-717
6. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., and Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348 (2003) 1309-1321
7. Connell J.M.C., Fraser R., and Davies E. Disorders of mineralocorticoid synthesis. Best Pract. Res. Clin. Endocrinol. Metab. 15 (2001) 43-60
8. Bureik M., Lisurek M., and Bernhardt R. The human steroid hydroxylases CYP11B1 and CYP11B2. Biol. Chem. 383 (2002) 1537-1551
9. 11β). J. Biol. Chem. 264 (1989) 20961-20967
10. Denner K., Doehmer J., and Bernhardt R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells. Endocr. Res. 21 (1995) 443-448
11. Ehmer P.B., Bureik M., Bernhardt R., Müller U., and Hartmann R.W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol. 81 (2002) 173-179
12. Voets M., Müller-Vieira U., Marchais-Oberwinkler S., and Hartmann R.W. Synthesis of amidinohydrazones and evaluation of their inhibitory effect towards aldosterone synthase (CYP11B2) and the formation of selected steroids. Arch. Pharm. Pharm. Med. Chem. 337 (2004) 411-416
13. Bureik M., Hübel K., Dragan C.-A., Scher J., Becker H., Lenz N., and Bernhardt R. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Mol. Cell. Endocrinol. 217 (2004) 249-254
14. Ulmschneider S., Müller-Vieira U., Klein C.D., Antes I., Lengauer T., and Hartmann R.W. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J. Med. Chem. 48 (2005) 1563-1575
15. Ulmschneider S., Müller-Vieira U., Mitrenga M., Hartmann R.W., Oberwinkler-Marchais S., Klein C.D., Bureik M., Bernhardt R., Antes I., and Lengauer T. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J. Med. Chem. 48 (2005) 1796-1805
16. Voets M., Antes I., Scherer C., Müller-Vieira U., Biemel K., Marchais-Oberwinkler S., and Hartmann R.W. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 49 (2006) 2222-2231
17. Ogishima T., Mitani F., and Ishimura Y. Isolation of aldosterone synthase cytochrome P-450 from zona glomerulosa mitochondria of rat adrenal cortex. J. Biol. Chem. 264 (1989) 10935-10938
18. Denner K., Vogel R., Schmalix W., Doehmer J., and Bernhardt R. Cloning and stable expression of the human mitochondrial cytochrome P45011B1 cDNA in V79 Chinese hamster cells and their application for testing of potential inhibitors. Pharmacogenetics 5 (1995) 89-96
19. Fiebeler A., Nussberger J., Shagdarsuren E., Rong S., Hilfenhaus G., Al-Saadi N., Dechend R., Wellner M., Meiners S., Maser-Gluth C., Jeng A.Y., Webb R.L., Luft F.C., and Muller D.N. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111 (2005) 3087-3094
20. Ménard J., Gonzalez M.-F., Guyene T.-T., and Bissery A. Investigation of aldosterone-synthase inhibition in rats. J. Hypertens. 24 (2006) 1147-1155
21. Fallo F., Pezzi V., Barzon L., Mulatero P., Veglio F., Sonino N., and Mathis J.M. Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. Eur. J. Endocrinol. 147 (2002) 795-802
22. Müller J. Aldosterone: the minority hormone of the adrenal cortex. Steroids 60 (1995) 2-9